Catalyst Crew Technologies Corp., a digital health and artificial intelligence technology company focused on emerging markets, announced the assignment of intellectual property assets to its wholly-owned Venezuelan operating subsidiary, Inversiones Long 33, C.A. The assets, previously held by CEO Dr. Kevin Rodan Levy, consist of three patents registered in Venezuela covering proprietary technologies called CardioAI, PulmoAI, and NeuroAI. These technologies are designed for data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
The assignment represents a strategic move to align intellectual property with the company's operating structure, positioning the subsidiary as the primary development and commercialization vehicle for its technology platform in the region. According to the company, consolidating intellectual property at the operating level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion initiatives. This structural alignment could potentially streamline operations and create clearer pathways for technology deployment in Latin American healthcare markets.
In addition to the Venezuelan patent assignment, Catalyst Crew Technologies intends to pursue expanded intellectual property protection for its technologies in additional jurisdictions worldwide as practical. This global IP strategy supports long-term platform development and potential international deployment of the company's digital health solutions. The company's focus on scalable healthcare solutions includes telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics designed to improve access, efficiency, and care coordination.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that aligning intellectual property within the operating structure represents an important step in building the company's platform. "Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships,, and, where appropriate, broader intellectual property protection strategies across additional markets," Levy explained. The company continues to advance development of its digital health and artificial intelligence platform with an emphasis on emerging markets, particularly Latin America.
The company's strategic initiatives can be followed through its corporate website at https://catalystcrewai.com and through filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The intellectual property consolidation and global protection strategy may have implications for healthcare technology development in emerging markets, potentially influencing how AI-driven medical solutions are deployed and commercialized in regions with growing demand for modernized healthcare delivery systems.


